DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-D-0575]

Guidance for Industry on Expedited Programs for Serious Conditions--Drugs and Biologics;

Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Expedited Programs for Serious Conditions--Drugs and Biologics." The purpose of this guidance is to provide a single resource for information on FDA’s policies and procedures related to expedited drug development and review programs.

The following programs are intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition (expedited programs): Fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. This guidance finalizes the draft guidance issued in June 2013.

DATES: Submit either electronic or written comments on Agency guidances at any time.

ADDRESSES: Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002; or the Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave.,
FDA is announcing the availability of a guidance for industry entitled "Expedited Programs for Serious Conditions--Drugs and Biologics." This guidance provides a single resource for information on FDA’s policies and procedures related to the following expedited programs for serious conditions: (1) Fast track designation, (2) breakthrough therapy designation, (3) accelerated approval, and (4) priority review designation. The guidance describes threshold criteria generally applicable to expedited programs, including what is meant by serious condition, unmet medical need, and available therapy. This guidance also discusses considerations for expedited development and review such as manufacturing and product quality, nonclinical studies, and clinical inspections. In addition, this guidance aligns CDER's criteria for priority review designation with CBER's criteria. Only products intended to treat a serious
condition are eligible for priority review (unless otherwise eligible under specific statutory provisions).

For over 30 years, expediting the availability of promising therapies to patients with serious conditions has been a priority for FDA. With the passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Public Law 112-122), FDA is expanding its efforts to expedite development and review of therapies intended to treat patients with serious conditions. This guidance is intended to satisfy the statutory requirements of sections 901(c)(2) and 902(b)(1)(A) of FDASIA.

Section 901(c)(2) of FDASIA requires FDA to issue a final guidance document to implement amendments to the Federal Food, Drug, and Cosmetic Act (the FD&C Act) made by section 901 of FDASIA (Enhancement of Accelerated Approval Access to New Medical Treatments) within 1 year of the date the draft guidance issues. The discussions of accelerated approval, and other more broadly applicable provisions in this guidance, are intended to meet this requirement.

Section 902(b)(1)(A) of FDASIA requires FDA to issue a guidance document to implement requirements of section 902 (Breakthrough Therapies) within 1 year of the date the comment period closes for the draft guidance. The breakthrough therapy discussion and other more broadly applicable provisions in this guidance are intended to meet this requirement.

In the Federal Register of June 26, 2013 (78 FR 38349), FDA announced the availability of the draft guidance entitled "Expedited Programs for Serious Conditions--Drugs and Biologics." The notice gave the public an opportunity to comment by August 26, 2013. FDA carefully considered all comments received in developing the final guidance. This guidance addresses the applicability of expedited programs to rare diseases, clarification on available
therapy, and additional detail on possible flexibility in manufacturing and product quality. The
guidance also includes clarification on the qualifying criteria for breakthrough therapy
designation and examples of surrogate endpoints and intermediate clinical endpoints used to
support accelerated approval. This guidance finalizes the draft guidance issued in June 2013.

The provisions of this guidance relating to fast track development and other issues such
as serious condition and unmet medical need, replace the guidance for industry entitled "Fast
Track Drug Development Programs--Designation, Development, and Application Review." The
provisions of this guidance pertaining to available therapy replace the guidance for industry
entitled "Available Therapy."

This guidance is being issued consistent with FDA's good guidance practices regulation
(21 CFR 10.115). The guidance represents the Agency's current thinking on expedited programs
for serious conditions--drugs and biologics. It does not create or confer any rights for or on any
person and does not operate to bind FDA or the public. An alternative approach may be used if
such approach satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

This guidance contains information collection provisions that are subject to review by the
Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44
356(b)(1), 379g, and 379h) have been approved under OMB control numbers 0910-0686, 0910-
0001, 0910-0338, 0910-0389, 0910-0297, and 0910-0765.
III. Comments

Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

IV. Electronic Access


Dated: May 23, 2014.

Leslie Kux,

Assistant Commissioner for Policy.